Michael A. Metzger - 14 Mar 2025 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
14 Mar 2025
Net transactions value
+$43,733
Form type
4
Filing time
17 Mar 2025, 06:01:11 UTC
Previous filing
06 Mar 2025
Next filing
02 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $43,733 +6,074 +2% $7.20 306,195 14 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock options (Right to buy) Options Exercise $0 +6,074 $0.000000 0 14 Mar 2025 Common Stock 6,074 $7.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested.